May 07, 2026 07:21 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Who after Mamata in Bengal? Amit Shah to meet BJP MLA-elects ahead of May 9 oath | Vijay’s TVK seeks Congress, Left support after falling short of majority in Tamil Nadu | Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres | Bangladesh MP warns of refugee crisis if BJP wins West Bengal polls | Diplomatic row: Bangladesh summons Indian envoy over Himanta Biswa Sarma remarks | Supreme Court grants Pawan Khera anticipatory bail in case over allegations against Himanta Biswa Sarma's wife | ‘Not necessary to humiliate me with arrest’: Pawan Khera to SC over remarks on Himanta Biswa Sarma’s wife | ‘Let’s not choose for people capable of choosing’: Supreme Court to Centre on teen pregnancy termination | I-PAC co-founder Vinesh Chandel gets bail after Bengal polls conclude | Exit Polls Give Bengal to BJP—But One Survey Begs to Differ

Lupin launches generic Aricept tablets in the US

| | Mar 31, 2016, at 09:23 pm
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
 
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
 
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm